CALLAN JMB INC.
Callan JMB provides thermal management logistics and fulfillment solutions for the life sciences industry, serving customers that ship temperature-sensitive products such as cell therapies, vaccines, diagnostic materials and biopharmaceuticals. Its services combine specialized packaging, information technology and cold chain logistics, with shipment information monitoring, recording and archiving for scientific and regulatory use. Its offerings include emergency preparedness and response, specialty temperature-regulating reusable packaging, fulfillment services and Sentry monitoring, which tracks shipment temperature, humidity and location. Callan JMB also provides Ship2Q inventory management software to manage its transportation network. It earns money from its logistics, packaging, monitoring and related services and products; its technical services are bundled with emergency response and packaging offerings rather than treated as separate revenue streams. Callan JMB is headquartered in Spring Branch, Texas.
No SEC Form 4 filings for $CJMB in the last 30 days.
See all $CJMB insider activity →Callan JMB raised $1.5 million in a private placement, selling 1.36 million shares at $1.10 each. The company's CEO and insiders participated. Proceeds will fund growth initiatives. Alexander Capital acted as agent, receiving a 6% fee and warrants.
CALLAN JMB INC. (CJMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Callan JMB CEO and Management Team Invest $1.5 Million in Common-Only Transaction at a Premium of $1.10 Per Share, Reinforcing Confidence in Growth Strategy SPRING BRANCH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Co
Callan JMB (CJMB) received QuickStrip oral thin-film production equipment from Rapid Dose, aiming to generate up to $15M in revenue over 18 months. The equipment supports domestic pharmaceutical manufacturing and aligns with the company's expansion strategy. No additional capital is needed for this project or a recently announced IV bag facility.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CJMB (CALLAN JMB INC.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 1 bearish.
Recent CJMB coverage spans corporate actions, financial news and mergers & acquisitions.
The dilutive common-stock raise at a fixed $1.10 price is likely to pressure near-term valuation, while insider-backed demand may limit downside.
Management’s premium buy signals confidence and may support near-term sentiment, but it is not a fundamental guidance or deal update.
Positive catalyst tied to manufacturing ramp, but revenue is conditional on installation, qualification, and commercial start.
Funding enables capacity expansion, potentially boosting future revenues.
Receiving the equipment could expand Callan JMB's logistics services into pharmaceutical manufacturing, but no operational start is confirmed.
AlphAI scores every news story that mentions CJMB with an AI model for sentiment and relevance, and aggregates insider trades from CALLAN JMB INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Callan JMB raised $1.5 million in a private placement, selling 1.36 million shares at $1.10 each. The company's CEO and insiders participated. Proceeds will fund growth initiatives. Alexander Capital acted as agent, receiving a 6% fee and warrants.
CALLAN JMB INC. (CJMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Callan JMB CEO and Management Team Invest $1.5 Million in Common-Only Transaction at a Premium of $1.10 Per Share, Reinforcing Confidence in Growth Strategy SPRING BRANCH, Texas, Nov. 12, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Co
Callan JMB (CJMB) received QuickStrip oral thin-film production equipment from Rapid Dose, aiming to generate up to $15M in revenue over 18 months. The equipment supports domestic pharmaceutical manufacturing and aligns with the company's expansion strategy. No additional capital is needed for this project or a recently announced IV bag facility.
Callan JMB Inc. (CJMB) will build a $16M IV bag plant funded by a third-party partnership. The facility is expected to generate $450M in annual revenue once operational, according to the company.
Rapid Dose Therapeutics (CSE: DOSE, OTCQB: RDTCF) shipped a QuickStrip™ production line to Callan JMB (NASDAQ: CJMB) for installation in Texas. The collaboration aims to support U.S. production of oral thin-film drugs, subject to agreements and regulatory approvals. Both companies see potential in combining RDT's technology with Callan JMB's logistics capabilities.
Callan JMB Inc. (CJMB) approved blueprints for a $16M IV bag plant in Alabama, expecting $450M in annual revenue. The facility will use automation and robotics, supporting healthcare supply chain resilience and emergency preparedness.
Callan JMB terminated its agreement to acquire 50% of oil and gas leases from Pfanenstiel Company due to insufficient due diligence, effective Oct 16, 2026. No fees were paid, and the company will not raise additional capital for this deal but may consider future talks on different terms.
CALLAN JMB INC. (CJMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed , on August 26, 2026, Callan Power LLC (the “ Buyer ”), a Nevada limited liability company and a wholly-owned subsidiary of Callan JMB Inc. (the “ Company ”), entered into an Asset Purchase and Sale Ag
Nasdaq notified Callan JMB (CJMB) of delisting due to insufficient stockholders' equity. The company requested a hearing, which temporarily halts trading suspension. Success of the appeal is uncertain.
Callan JMB Inc. (CJMB) announced a $28M equipment investment for U.S. pharmaceutical manufacturing at the Atlas Complex in Alabama, partnering with TRUKING. The company will also distribute and assemble TRUKING equipment, expanding its role in pharmaceutical infrastructure. Initial production is targeted for late 2027, subject to regulatory approvals.
